Compare APLE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | TLX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2007 | N/A |
| Metric | APLE | TLX |
|---|---|---|
| Price | $16.84 | $10.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $13.00 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 2.6M | 181.0K |
| Earning Date | 05-04-2026 | 08-19-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,238,622,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.35 | N/A |
| P/E Ratio | ★ $139.04 | $150.33 |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $6.28 |
| 52 Week High | $17.06 | $16.85 |
| Indicator | APLE | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 49.35 |
| Support Level | $15.99 | $9.42 |
| Resistance Level | N/A | $11.38 |
| Average True Range (ATR) | 0.33 | 0.26 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 80.84 | 11.82 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.